LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:40 a.m. Eastern Time.
There will be simultaneous and archived webcasts available at Click Here and www.radnet.com under the “News and Press Releases” sub-menu of the website.
Details for RadNet's Presentation:
Date: | Monday, June 10, 2024 |
Time: | 8:40 a.m. Eastern Time |
Location: | Miami, FL |
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 375 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, Texas and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,700 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$50.67 |
Daily Change: | -0.05 -0.10 |
Daily Volume: | 786,970 |
Market Cap: | US$3.750B |
March 13, 2025 February 27, 2025 February 26, 2025 February 26, 2025 February 25, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load